Myderm

Quick links to important sections

Myderm

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Myderm

Quick Facts

Property Description
Active Ingredients Beclometasone, Clotrimazole, Gentamicin
Form Cream or Ointment (Topical preparation)
Pharmacological Class Triple combination Glucocorticoid, Antifungal, and Aminoglycoside Antibiotic
Common Purpose Managing dermatoses complicated by mixed infections
Origin Synthetic compounds (Fixed-dose combination)

What Type of Medicine is Myderm and How is it Classified?

Myderm is a synthetic, multicomponent topical preparation classified as a Fixed-dose combination (FDC) medicine for cutaneous application. This dermatological product integrates three distinct pharmacological agents. Its composition includes the potent Glucocorticoid Beclometasone dipropionate, the Imidazole antifungal agent Clotrimazole, and the Aminoglycoside antibiotic Gentamicin sulfate. The drug is supplied for external use in the form of a Cream or an Ointment base.

This classification as a Triple combination preparation is the key differentiating factor, making it distinct from single-agent formulations. While various topical products contain corticosteroids or antibiotics individually, Myderm is specifically positioned for patients where infection (both fungal and bacterial) and significant inflammation are known to coexist, which is a common occurrence in chronic or refractory dermatoses.


What is Myderm's Triple Composition and General Purpose?

Myderm's composition consists of the principal Active ingredients: Beclometasone dipropionate, Clotrimazole, and Gentamicin sulfate. Each component serves a distinct, verified function within the product. The Beclometasone reduces symptoms by exerting a potent Anti-inflammatory effect and antipruritic effect on the skin. Gentamicin provides the necessary Bactericidal action against susceptible bacterial strains, while Clotrimazole works as a fungicidal agent against common superficial fungal pathogens.

The general purpose of this FDC is to provide management for dermatoses (skin inflammation) that are complicated by or highly susceptible to mixed skin infections involving both fungi and bacteria. By integrating these three agents, Myderm aims to quickly mitigate symptoms while simultaneously tackling the underlying fungal and bacterial pathogens, offering a focused solution for complex superficial skin issues.

Regulatory References

  1. NIH StatPearls - Gentamicin

What side effects are possible with Myderm?

Possible Side Effects and Safety Information

Official regulatory documentation organizes the safety profile of this triple combination (Beclometasone, Clotrimazole, Gentamicin) based on the affected body systems and frequency of occurrence. The majority of reported adverse reactions are localized to the application site.


Documented Adverse Reaction Scope

Classification Affected System-Organ Classes
Common / Infrequent Skin and Subcutaneous Tissue Disorders (e.g., burning sensation, irritation, dryness, itching, redness, folliculitis).
Systemic Risk Endocrine System Disorders (HPA axis suppression, manifestations of Cushing's syndrome), Eye Disorders (Cataracts, Glaucoma), Ear and Labyrinth Disorders (Ototoxicity potential), Renal and Urinary Disorders (Nephrotoxic potential).

Serious Adverse Reactions

Systemic effects are considered serious adverse reactions. Regulatory labels document the potential for reversible Hypothalamic-Pituitary-Adrenal (HPA) axis suppression related to the corticosteroid component. The absorption of Gentamicin may carry a documented risk of irreversible Ototoxicity (hearing loss) and Nephrotoxic potential (kidney toxicity), particularly when high systemic exposure occurs.


Safety Constraints and Population Notes

The risk of adverse reactions is linked to the extent of exposure. Prolonged use and application over a large surface area increase the risk of systemic side effects. Official safety statements indicate that pediatric patients may exhibit greater susceptibility to systemic toxicity, including adrenal suppression, due to their skin-surface-to-body mass ratio. The product is contraindicated in individuals with a known hypersensitivity to any of the active ingredients.

Overdose and Emergency Response

Overdose and when to seek help

The overdose profile for this topical medicine is defined by systemic risks arising from the absorption of the potent corticosteroid (Beclometasone) and aminoglycoside antibiotic (Gentamicin) components through the skin. Prolonged or excessive use, application to large surface areas, or use under occlusive dressings are documented factors that increase the potential for these systemic effects.

Potential Systemic Manifestations Required Emergency Actions
Glucocorticoid Excess: HPA axis suppression or features consistent with Cushing's Syndrome. Seek immediate medical attention or contact emergency services upon suspicion of overdose or accidental ingestion.
Aminoglycoside Toxicity: Potential for nephrotoxicity (impaired renal function) and ototoxicity (auditory/vestibular damage). Immediate medical help is mandated if signs of systemic toxicity are observed.

Overdose management is officially described as symptomatic and supportive treatment. For confirmed HPA axis suppression, regulatory procedures mandate the gradual withdrawal of the medicine under medical supervision. Manifestations such as irreversible hearing loss and renal impairment are classified as serious potential outcomes. Regulatory documents also note an increased susceptibility in the pediatric population to systemic effects. No specific antidote is known for the Beclometasone or Clotrimazole components.

Therapeutic Uses of Myderm

What Myderm Treats: Main Uses and Benefits

Treating Inflammatory Dermatoses with Mixed Infections

Myderm is generally used to help with symptom clusters related to inflammatory or irritative states that present with secondary infection. It is applied in situations involving certain distressing symptoms where skin inflammation, generally associated with dermatitis or eczema, is considered relevant in conditions involving episodic or fluctuating manifestations. This combination provides support that helps ease the overall symptom burden when symptoms are linked to inflammatory or irritative states.

The medication is considered relevant in conditions where symptoms may intensify temporarily, including symptom clusters common in tinea infections, seborrheic dermatitis, contact dermatitis, or other skin issues, particularly when secondary bacterial contamination is present.

“This action assists with maintaining functional stability and supports the patient during difficult episodes by easing distress when symptoms become temporarily overwhelming.”

Quick Fact: Relief for Complex Skin Discomfort

Property Description
Primary Symptom Focus Symptoms related to inflammatory or irritative states, including itching (pruritus), redness, and localized swelling
Main Therapeutic Goal Relevant when supportive symptom management is appropriate
Patient Benefit Contributes to improved comfort during symptomatic periods

Regulatory References

  1. Rwanda FDA Product Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Myderm?

The population eligibility for using Myderm, a triple combination topical medicine, is strictly governed by regulatory classifications based on the drug’s components (Beclometasone, Clotrimazole, Gentamicin).

Contraindicated Populations

Myderm must not be used by individuals with a known hypersensitivity to any of its active ingredients or components. It is formally contraindicated in patients with certain pre-existing skin conditions, including rosacea, acne vulgaris, perioral dermatitis, and perianal/genital pruritus. Use is also strictly prohibited in the presence of primary cutaneous viral infections such as Herpes simplex or Varicella (Chickenpox).

Age and Condition Restrictions

Population Group Regulatory Status
Pediatric Use (under 17 years) Safety and effectiveness are not established. Use is contraindicated under the age of three.
Pregnancy Not recommended during the first trimester; conditional use only if medically essential thereafter.
Renal/Hepatic Impairment Use requires caution due to the risk of systemic absorption of Gentamicin, particularly in cases of compromised organ function.

For adults who meet the labeled indication criteria, Myderm use is approved, but long-term continuous therapy is discouraged.

What should I know about interactions with other medicines?

The official interaction profile for Myderm primarily addresses risks arising from the potential for systemic absorption of its three active components. Categories of medicinal products with documented interaction potential include other Corticosteroids (topical or systemic), agents with Nephrotoxic or Ototoxic properties, Neuromuscular Blocking Agents, and strong CYP3A4 Inhibitors (e.g., Ritonavir, Cobicistat). These interactions are considered relevant when the product is applied to large areas, for prolonged periods, or to broken skin, which increases the likelihood of systemic effects.

A key consideration noted in the regulatory documents is the enhanced risk of nephrotoxicity and ototoxicity in pediatric patients and individuals with renal or hepatic impairment, underscoring the population-specific nature of certain interaction severities. The official documents state that no timing-based separation rules are required for the topical formulation, and no interactions are formally documented with food, alcohol, or herbal products.

Official interaction statements:

  • Co-administration with other corticosteroids increases the systemic exposure to the Beclometasone component, raising the risk for systemic corticosteroid effects.
  • Nephrotoxic and ototoxic medicines should be used cautiously due to the potential for additive toxicity from the Gentamicin component.
  • Following systemic absorption, Gentamicin may intensify and prolong the effects of neuromuscular blocking agents.

The regulatory interaction profile is defined by two mechanisms: the risk of pharmacodynamic reinforcement with other organ-toxic agents, and the potential for increased exposure of the corticosteroid component when combined with other steroid products. The profile makes the clinical relevance of these interactions contingent upon the extent of drug absorption from the application site.

Mechanism of Action

How Myderm Works: The Core Mechanisms

The mechanism of action involves three distinct agents targeting three separate biological systems—the host's inflammatory response, fungal cell viability, and bacterial protein synthesis—which together initiate distinct molecular actions.


Modulating Excessive Host Response

The corticosteroid component acts as an agonist of the Glucocorticoid Receptor ( GR), initiating a cascade that leads to the induction of Annexin A1. This protein inhibits the Phospholipase A2 ( PLA2) enzyme, thereby blocking the upstream pathway responsible for generating potent inflammatory mediators like Prostaglandins and Leukotrienes. This molecular suppression results in dermal vasoconstriction and minimizes the local synthesis of pro-inflammatory mediators, physiologically dampening the local vascular and cellular response.


Dual-Action Pathogen Disruption

The two anti-infective components execute simultaneous, distinct mechanisms that result in the disruption and lysis of microorganisms. The antifungal component inhibits Lanosterol 14-alpha -demethylase ( L-14DM), causing a critical depletion of Ergosterol and structural failure of the fungal cell membrane. Concurrently, the antibiotic component binds irreversibly to the 30S ribosomal subunit of bacteria, inducing misreading of the genetic code. This action forces the synthesis of non-functional proteins, leading to structural compromise of the bacterial cell and resulting in bactericidal activity.


Mechanistic Complementarity

The mechanism is defined by additive and complementary pharmacodynamics. The rapid action of the corticosteroid in modulating host inflammatory signaling allows the sustained, anti-pathogen mechanisms of the antifungal and antibiotic agents to execute their cell disruption cascades. This coordinated action results in the concurrent modulation of host signaling and the disruption of microbial cell viability.

Dosage and Administration Information

How to Use Myderm: Administration Guidelines

This section describes the high-level, standardized usage principles for Myderm (Beclometasone + Clotrimazole + Gentamicin topical combination).


Administration Scope

Feature Instruction
Route of administration Topical (or Cutaneous) application only.
Dosing schedule Apply a thin film or a small amount to the affected area. The total weekly quantity must not exceed 45 grams of the product.
Age-group administration rules Use in pediatric patients requires strict minimization of the amount and duration. No dose adjustment is required for older adults.
Missed-dose rules If an application is missed, it should be applied as soon as it is remembered, then the patient should resume the regular schedule.

Instruction Classifications (High-Level)

Classification Specification
Administration method type Topical (Cream or Ointment)
Frequency pattern Twice daily (typically morning and evening).
Use-context constraints Avoid occlusive dressings (e.g., bandages or wraps) unless explicitly directed, and avoid application to the face or underarms.
Duration constraint Treatment is limited to short courses (e.g., maximum 2 to 4 weeks), and treatment must be reviewed if symptoms show no clinical improvement within the designated period.

Connection to the Overall Use Protocol

The instructions establish that Myderm is strictly limited to twice-daily topical application with precise constraints on both quantity and duration, emphasizing that the total dose must not exceed 45 grams per week. These rules define the standardized method for administering the triple-combination product, explicitly restricting use under occlusion or on sensitive areas like the face to prevent unintended systemic absorption, thus structuring the entire use protocol as a short-term, targeted intervention.

Recent Clinical Evidence

Research evidence / Overview of studies


Evidence for Acute Pain Management

Research has explored the combination drug in the context of acute lower back pain. Studies examined its effects and safety profile in short-term use (up to 7 days).

  • Effects in Acute Low Back Pain: One large-scale trial reported that patients taking the combination showed a decrease in pain scores, with a larger change observed compared to the placebo group. The trial was a randomized, double-blind study involving 500 adults with acute, non-radicular lower back pain. A separate meta-analysis of three similar trials investigated whether the combination demonstrated greater change on pain intensity than ibuprofen alone.
  • Post-Surgical Pain: Research findings reported a difference in a study of combination therapy for post-surgical pain compared to monotherapy. This research focused on the initial 48-hour period following minor orthopedic procedures.

Evidence for Chronic Conditions

Studies investigated whether the drug is associated with reduced pain and increased mobility in people with chronic osteoarthritis, specifically in the knee and hip joints. The studies examined were typically 12 weeks in duration.

  • Osteoarthritis Pain: Findings were mixed. Some small-scale research showed a statistically significant change in the WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) pain subscale in favor of the combination drug. Other larger trials did not report a clinically relevant difference compared to a standard non-steroidal anti-inflammatory drug (NSAID). Evidence remains limited regarding effects over periods longer than 6 months.

Pharmacological and Safety Studies

Studies focused on how the medication is processed by the body and its potential adverse events.

  • Component Characteristics: The component's properties were studied in relation to key pain pathways. The studies examined the half-life and metabolite activity of both active ingredients.
  • Safety Profile: Research on administration explored taking the medication with food to see if it minimizes stomach irritation. Long-term use was examined in studies, which involved routine liver function checks. Trials investigated whether the combination drug demonstrated differences in the occurrence of gastrointestinal (GI) bleeding compared to single-agent NSAID therapy. Findings suggested no statistically significant difference in rates of severe GI adverse events over 3 months of use.

Key Studies & References

  1. An integrated safety analysis of combined acetaminophen and ibuprofen: Fixed-dose combination in pain management
  2. Drug combinations found to increase upper gastrointestinal bleeding risk

Frequently Asked Questions (FAQ)

Common questions about Myderm (FAQ)


Q: How quickly should I expect to see results after starting Myderm?

Official guidelines state that treatment must be reviewed if symptoms show no clinical improvement within a maximum of 2 to 4 weeks. This suggests that some level of response or improvement is generally expected within this timeframe. If there is no improvement in the condition after this period, regulatory information suggests a review of the treatment may be necessary.


Q: Does Myderm cure the skin condition or just manage the symptoms?

Myderm is classified as a medicine intended to manage dermatoses that are complicated by infections. Its action involves providing anti-inflammatory effects and simultaneously working against the underlying fungal and bacterial pathogens. While it tackles the root microbial causes, official documentation frames its use as a short-term management of the overall symptoms and condition.


Q: Are there any common over-the-counter products that interact badly with Myderm?

Regulatory documents list interaction potentials with specific classes of prescription drugs, such as other corticosteroids and certain kidney- or ear-toxic agents. However, official information does not specifically document formal interactions with common, non-herbal, over-the-counter products. It is important to inform a healthcare provider of all products being used, including OTC items.


Q: Is Myderm safe to use on the face or sensitive areas?

Official administration instructions generally advise against application to the face or underarms. This constraint is in place because the skin in these areas is highly sensitive and prone to increased systemic absorption of the active ingredients, which can raise the risk of systemic side effects.


Q: Does Myderm need to be applied every day, or only when symptoms flare up?

Myderm is intended for use in short, continuous courses, typically for a maximum of 2 to 4 weeks, with a twice daily application pattern. The product information indicates that intermittent use during flares or stopping prematurely may not align with the short, continuous course of treatment required to address the infection.


Q: Is it normal to feel a slight burning sensation when first applying Myderm?

Yes, regulatory product information lists a burning sensation as a common or infrequent adverse reaction that occurs locally at the application site. Other common localized reactions may include irritation or redness. If the sensation is severe or continues, official guidance suggests following the advice of a healthcare professional.


Q: What should I do if I accidentally get Myderm in my eyes?

Regulatory safety information emphasizes that contact with sensitive areas such as the eyes, nose, mouth, or vagina must be avoided. If accidental contact occurs, official safety information states the area should be rinsed thoroughly with water.


Q: Does Myderm have any known interactions with herbal supplements like St. John's Wort?

Official regulatory documents do not formally document interactions with specific herbal products. Caution is always advised when combining any prescription medicine with supplements. It remains important to inform a healthcare provider of all supplements being taken.


Q: Can Myderm cause a rash that wasn't there before?

Yes, common side effects are often localized to the skin and may manifest as irritation or redness, which could resemble a new rash. If a significant rash or worsening symptoms develop, it could also be a sign of an allergic reaction or worsening irritation.


Q: Is there a possibility of an allergic reaction to Myderm?

Yes, as with any medicine, there is a possibility of an allergic reaction. The product is contraindicated (must not be used) in patients with a known hypersensitivity to any of its active components. If signs of a severe allergic reaction are observed, medical attention should be sought.


Q: Can using too much Myderm make the condition worse?

The administration guidelines strictly limit the amount of Myderm that should be applied. Applying too thick a film or using it over large areas can lead to increased systemic absorption of the corticosteroid and antibiotic components. This increased absorption can raise the risk of serious systemic side effects, such as adrenal suppression.


Q: What happens if I stop using Myderm suddenly?

The corticosteroid component carries a risk of Hypothalamic-Pituitary-Adrenal (HPA) axis suppression if absorbed systemically, especially with prolonged use. While Myderm is only used for short courses, sudden cessation after extended use could theoretically result in withdrawal effects. Consulting a prescriber's advice is recommended when discontinuing use.


Q: What is the average duration of treatment with Myderm?

The administration rules limit the treatment to a short course, typically lasting a maximum of 2 to 4 weeks. Treatment duration is kept brief to minimize the risk of systemic absorption and related side effects from the corticosteroid and antibiotic components.


Q: Why do doctors prescribe Myderm for eczema?

Myderm is indicated for managing dermatoses (skin inflammation) that are complicated by or susceptible to mixed infections. Eczema (or dermatitis) is a common inflammatory dermatosis, and the medicine's three-part formulation is designed to treat both the inflammation and any accompanying fungal or bacterial infection frequently found with such conditions.


Q: Can Myderm be used on broken or infected skin?

Regulatory documents advise caution and generally restrict application to large surface areas or damaged skin due to the risk of increased systemic absorption of the active components, particularly the antibiotic Gentamicin. This is due to the potential for serious side effects like kidney or inner ear toxicity.


Q: Are there any dietary restrictions needed while using Myderm?

No. Official regulatory documents do not specify any required dietary restrictions. They explicitly state that no formal interactions are documented with food or alcohol for this topical product.


Q: Is Myderm a targeted treatment, or does it affect the whole body?

Myderm is a targeted, topical treatment meant to work directly on the skin at the application site. However, official warnings note that with misuse, such as applying it to large areas or for prolonged periods, there is a risk of systemic absorption, which means the medicine can enter the bloodstream and affect the whole body.


Q: Do other medications like antifungals or antibiotics affect Myderm's action?

Official information indicates that using Myderm with other corticosteroids increases the systemic exposure to the Myderm's corticosteroid component. Furthermore, caution is advised with other medicines that are toxic to the kidney or ear, due to the potential for additive toxicity from the Gentamicin component.


Q: Why is Myderm not recommended for some fungal infections?

Myderm is strictly contraindicated in the presence of primary cutaneous viral infections, such as chickenpox or herpes simplex. Since it contains a corticosteroid, using it on such an infection could worsen the condition. Therefore, proper diagnosis is crucial before use.


Q: Does Myderm interact with common supplements like Vitamin D or fish oil?

Official information states that no formal interactions are documented with food or herbal products. This generally implies that no known harmful interactions are expected with common dietary supplements like Vitamin D or fish oil when Myderm is used correctly and topically.


Q: If an application is missed, what is the best time to apply the missed dose?

According to official product information, if an application is missed, it should be applied as soon as it is remembered. After applying the missed dose, the patient should then resume the regular schedule for subsequent applications.

How should Myderm be stored and disposed of?

How to Store and Dispose of Myderm

Official regulatory information specifies strict conditions for storing and disposing of Myderm (Beclometasone, Clotrimazole, Gentamicin topical combination) to maintain its quality and ensure safety.


Storage Requirements

Myderm must be stored in a cool and dry place, with the temperature not exceeding 30 C. The product must not be frozen and requires protection from light. It is mandatory to keep the medicine in the original container with the cap tightly closed and stored out of the sight and reach of children.


Disposal Instructions

Disposal of any unused or expired product must be carried out in accordance with local or national regulations. Explicit instructions require users to take measures to avoid release to the environment, often necessitating disposal through an approved waste disposal plant.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Myderm found in:

A-Z Index: